OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial
Overactive bladder affects 12% to 17% of the general population and almost a third experience urinary incontinence, which may severely impact health related quality of life. Oral anticholinergics are the mainstay of pharmacological treatment but they are limited by inadequate efficacy or side effect...
Gespeichert in:
| Veröffentlicht in: | The Journal of urology Jg. 197; H. 2S; S. S216 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
01.02.2017
|
| Schlagworte: | |
| ISSN: | 1527-3792, 1527-3792 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Overactive bladder affects 12% to 17% of the general population and almost a third experience urinary incontinence, which may severely impact health related quality of life. Oral anticholinergics are the mainstay of pharmacological treatment but they are limited by inadequate efficacy or side effects, leading to a high discontinuation rate. We report the results of the first large (557 patients), phase 3, placebo controlled trial of onabotulinumtoxinA in patients with overactive bladder and urinary incontinence inadequately managed with anticholinergics.
Eligible patients with overactive bladder, 3 or more urgency urinary incontinence episodes in 3 days and 8 or more micturitions per day were randomized 1:1 to receive intradetrusor injection of onabotulinumtoxinA 100 U or placebo. Co-primary end points were the change from baseline in the number of urinary incontinence episodes per day and the proportion of patients with a positive response on the treatment benefit scale at posttreatment week 12. Secondary end points included other overactive bladder symptoms and health related quality of life. Adverse events were assessed.
OnabotulinumtoxinA significantly decreased the daily frequency of urinary incontinence episodes vs placebo (-2.65 vs -0.87, p <0.001) and 22.9% vs 6.5% of patients became completely continent. A larger proportion of onabotulinumtoxinA than placebo treated patients reported a positive response on the treatment benefit scale (60.8% vs 29.2%, p <0.001). All other overactive bladder symptoms improved vs placebo (p ≤0.05). OnabotulinumtoxinA improved patient health related quality of life across multiple measures (p <0.001). Uncomplicated urinary tract infection was the most common adverse event. A 5.4% rate of urinary retention was observed.
OnabotulinumtoxinA 100 U showed significant, clinically relevant improvement in all overactive bladder symptoms and health related quality of life in patients inadequately treated with anticholinergics and was well tolerated. |
|---|---|
| AbstractList | Overactive bladder affects 12% to 17% of the general population and almost a third experience urinary incontinence, which may severely impact health related quality of life. Oral anticholinergics are the mainstay of pharmacological treatment but they are limited by inadequate efficacy or side effects, leading to a high discontinuation rate. We report the results of the first large (557 patients), phase 3, placebo controlled trial of onabotulinumtoxinA in patients with overactive bladder and urinary incontinence inadequately managed with anticholinergics.PURPOSEOveractive bladder affects 12% to 17% of the general population and almost a third experience urinary incontinence, which may severely impact health related quality of life. Oral anticholinergics are the mainstay of pharmacological treatment but they are limited by inadequate efficacy or side effects, leading to a high discontinuation rate. We report the results of the first large (557 patients), phase 3, placebo controlled trial of onabotulinumtoxinA in patients with overactive bladder and urinary incontinence inadequately managed with anticholinergics.Eligible patients with overactive bladder, 3 or more urgency urinary incontinence episodes in 3 days and 8 or more micturitions per day were randomized 1:1 to receive intradetrusor injection of onabotulinumtoxinA 100 U or placebo. Co-primary end points were the change from baseline in the number of urinary incontinence episodes per day and the proportion of patients with a positive response on the treatment benefit scale at posttreatment week 12. Secondary end points included other overactive bladder symptoms and health related quality of life. Adverse events were assessed.MATERIALS AND METHODSEligible patients with overactive bladder, 3 or more urgency urinary incontinence episodes in 3 days and 8 or more micturitions per day were randomized 1:1 to receive intradetrusor injection of onabotulinumtoxinA 100 U or placebo. Co-primary end points were the change from baseline in the number of urinary incontinence episodes per day and the proportion of patients with a positive response on the treatment benefit scale at posttreatment week 12. Secondary end points included other overactive bladder symptoms and health related quality of life. Adverse events were assessed.OnabotulinumtoxinA significantly decreased the daily frequency of urinary incontinence episodes vs placebo (-2.65 vs -0.87, p <0.001) and 22.9% vs 6.5% of patients became completely continent. A larger proportion of onabotulinumtoxinA than placebo treated patients reported a positive response on the treatment benefit scale (60.8% vs 29.2%, p <0.001). All other overactive bladder symptoms improved vs placebo (p ≤0.05). OnabotulinumtoxinA improved patient health related quality of life across multiple measures (p <0.001). Uncomplicated urinary tract infection was the most common adverse event. A 5.4% rate of urinary retention was observed.RESULTSOnabotulinumtoxinA significantly decreased the daily frequency of urinary incontinence episodes vs placebo (-2.65 vs -0.87, p <0.001) and 22.9% vs 6.5% of patients became completely continent. A larger proportion of onabotulinumtoxinA than placebo treated patients reported a positive response on the treatment benefit scale (60.8% vs 29.2%, p <0.001). All other overactive bladder symptoms improved vs placebo (p ≤0.05). OnabotulinumtoxinA improved patient health related quality of life across multiple measures (p <0.001). Uncomplicated urinary tract infection was the most common adverse event. A 5.4% rate of urinary retention was observed.OnabotulinumtoxinA 100 U showed significant, clinically relevant improvement in all overactive bladder symptoms and health related quality of life in patients inadequately treated with anticholinergics and was well tolerated.CONCLUSIONSOnabotulinumtoxinA 100 U showed significant, clinically relevant improvement in all overactive bladder symptoms and health related quality of life in patients inadequately treated with anticholinergics and was well tolerated. Overactive bladder affects 12% to 17% of the general population and almost a third experience urinary incontinence, which may severely impact health related quality of life. Oral anticholinergics are the mainstay of pharmacological treatment but they are limited by inadequate efficacy or side effects, leading to a high discontinuation rate. We report the results of the first large (557 patients), phase 3, placebo controlled trial of onabotulinumtoxinA in patients with overactive bladder and urinary incontinence inadequately managed with anticholinergics. Eligible patients with overactive bladder, 3 or more urgency urinary incontinence episodes in 3 days and 8 or more micturitions per day were randomized 1:1 to receive intradetrusor injection of onabotulinumtoxinA 100 U or placebo. Co-primary end points were the change from baseline in the number of urinary incontinence episodes per day and the proportion of patients with a positive response on the treatment benefit scale at posttreatment week 12. Secondary end points included other overactive bladder symptoms and health related quality of life. Adverse events were assessed. OnabotulinumtoxinA significantly decreased the daily frequency of urinary incontinence episodes vs placebo (-2.65 vs -0.87, p <0.001) and 22.9% vs 6.5% of patients became completely continent. A larger proportion of onabotulinumtoxinA than placebo treated patients reported a positive response on the treatment benefit scale (60.8% vs 29.2%, p <0.001). All other overactive bladder symptoms improved vs placebo (p ≤0.05). OnabotulinumtoxinA improved patient health related quality of life across multiple measures (p <0.001). Uncomplicated urinary tract infection was the most common adverse event. A 5.4% rate of urinary retention was observed. OnabotulinumtoxinA 100 U showed significant, clinically relevant improvement in all overactive bladder symptoms and health related quality of life in patients inadequately treated with anticholinergics and was well tolerated. |
| Author | Yan, Xiaohong Thompson, Catherine Nitti, Victor W Haag-Molkenteller, Cornelia Herschorn, Sender Nardo, Christopher Dmochowski, Roger Sand, Peter |
| Author_xml | – sequence: 1 givenname: Victor W surname: Nitti fullname: Nitti, Victor W email: Victor.Nitti@nyumc.org organization: New York University Urology Associates, New York, New York. Electronic address: Victor.Nitti@nyumc.org – sequence: 2 givenname: Roger surname: Dmochowski fullname: Dmochowski, Roger organization: Vanderbilt University, Nashville, Tennessee – sequence: 3 givenname: Sender surname: Herschorn fullname: Herschorn, Sender organization: University of Toronto, Toronto, Ontario, Canada – sequence: 4 givenname: Peter surname: Sand fullname: Sand, Peter organization: University of Chicago, Evanston, Illinois – sequence: 5 givenname: Catherine surname: Thompson fullname: Thompson, Catherine organization: Allergan, Ltd., Marlow, Buckinghamshire, United Kingdom – sequence: 6 givenname: Christopher surname: Nardo fullname: Nardo, Christopher organization: Allergan, Inc., Irvine, California – sequence: 7 givenname: Xiaohong surname: Yan fullname: Yan, Xiaohong organization: Allergan, Inc., Irvine, California – sequence: 8 givenname: Cornelia surname: Haag-Molkenteller fullname: Haag-Molkenteller, Cornelia organization: Allergan, Inc., Irvine, California |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28012773$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkNtqGzEQhkVxaey0L9CLMpe9sN2VdrWH3iUmJwjYBPva6DCLZbRSKmmdNu-Sd41oUujNzM_w_98wMyMT5x0S8pUWS1rQ-sdxeRyDX7Ksl39n3QcypZw1i7Lp2OQ_fUZmMR6Lgla8YZ_IGWsLypqmnJKXtRPSp9EaNw7J_zbuAnofIB0QtgFFGtAl8D1sRDJZRngy6QDrEwahkjkhXFqhNQYQTsMuGCfCH7hzyrtkHDqFP-EB42hzMlMEbA4iIpRzeMgBP5hn1HPYWKFQeljlVPDWos7LjbCfycde2Ihf3vs52V1fbVe3i_v1zd3q4n6hSlanhS4V12UnRVvURZkLlZK2mooqY_u6Qt7XXa215G3VyEor1bKe11hlG-edZOfk-xv3MfhfI8a0H0xUaK1w6Me4py3vGs7btsvWb-_WUQ6o94_BDPnk_b-XsldBoX4w |
| CitedBy_id | crossref_primary_10_1007_s11934_018_0844_6 crossref_primary_10_1002_nau_25370 crossref_primary_10_1177_20514158251364043 crossref_primary_10_1007_s11255_022_03107_6 crossref_primary_10_1002_mds_27072 crossref_primary_10_1007_s00192_025_06047_8 crossref_primary_10_1007_s00192_021_04712_2 crossref_primary_10_3390_toxins15050338 crossref_primary_10_1016_j_acuro_2020_11_013 crossref_primary_10_1002_nau_25054 crossref_primary_10_1002_cnm_3318 crossref_primary_10_1007_s00192_019_04007_7 crossref_primary_10_1002_nau_24207 crossref_primary_10_1016_j_pharep_2018_08_002 crossref_primary_10_1002_nau_24326 crossref_primary_10_1007_s40746_024_00314_4 crossref_primary_10_3390_biomedicines13092147 crossref_primary_10_3389_fphar_2022_840695 crossref_primary_10_1007_s40266_022_00950_1 crossref_primary_10_1007_s11884_018_0462_7 crossref_primary_10_3390_toxins16060261 crossref_primary_10_3390_toxins16100420 crossref_primary_10_1002_nau_24797 crossref_primary_10_1002_nau_24871 crossref_primary_10_1097_JU_0000000000004189 crossref_primary_10_3389_fmed_2022_746064 crossref_primary_10_1002_nau_25000 crossref_primary_10_1002_nau_24936 crossref_primary_10_1055_a_1924_7517 crossref_primary_10_1111_ijcp_13027 crossref_primary_10_1007_s11884_017_0417_4 crossref_primary_10_1002_nau_24879 crossref_primary_10_1007_s11884_017_0454_z crossref_primary_10_1016_j_euf_2018_05_004 crossref_primary_10_1097_MOU_0000000000000843 crossref_primary_10_1016_j_acuroe_2020_11_012 crossref_primary_10_1007_s00192_021_04688_z crossref_primary_10_3390_jcm12041462 crossref_primary_10_4103_tcmj_tcmj_313_21 crossref_primary_10_12688_f1000research_16356_1 crossref_primary_10_1007_s11255_021_02802_0 |
| ContentType | Journal Article |
| Contributor | Huff, N A Simmons, G Kalota, S Efros, M Moseley, W Werner, M A Archer-Goode, C L Mutchnik, S Whitmore, K Andreou, C Goldfarb, B Leach, G E Freedman, S Maxwell, K Schiff, W Tietjen, D N Moore, C K Gaylis, F Rockove, S Mahoney, J Lotenfoe, R R Fialkov, J M Siegel, S Beam, T D Kane, R Jalkut, M W Snyder, J Sussman, D Antoci, J P Hlavinka, T C Kaplan, M M Goldman, H Cline, K Kaminetsky, J Shenot, P D'Anna, R E Zusman, E Gousse, A Peters-Gee, J M Kriteman, L S Eiley, D Dmochowski, R R Berger, Y Payne, C K Radomski, S Bradford, R S Sutherland, S E Viselli, A Mynatt, R J Siami, P Jacoby, K Lipsitz, D U Becker, J M Leng, W W Pommerville, P J Auerbach, S M Hertzman, B L Hazan, L Margolis, E J Klutke, C G Torgerson, E Steinhoff, G Pettit, P Krejci, K Sand, P K King-Menzner, D Biester, R J Williams, T Wurzel, R Grunberger, I Lumerman, J Johnson, A R Herschorn, S Josephson, D Hale, D S Blick, S D Roberts, B J Aliotta, P Burzon, D T Park, G Klimberg, I W Khorsandi, M Nitti, V Ginsberg, D Egerdie, R B |
| Contributor_xml | – sequence: 1 givenname: C surname: Andreou fullname: Andreou, C – sequence: 2 givenname: R B surname: Egerdie fullname: Egerdie, R B – sequence: 3 givenname: D surname: Eiley fullname: Eiley, D – sequence: 4 givenname: B surname: Goldfarb fullname: Goldfarb, B – sequence: 5 givenname: S surname: Herschorn fullname: Herschorn, S – sequence: 6 givenname: J surname: Mahoney fullname: Mahoney, J – sequence: 7 givenname: P J surname: Pommerville fullname: Pommerville, P J – sequence: 8 givenname: S surname: Radomski fullname: Radomski, S – sequence: 9 givenname: G surname: Steinhoff fullname: Steinhoff, G – sequence: 10 givenname: P surname: Aliotta fullname: Aliotta, P – sequence: 11 givenname: J P surname: Antoci fullname: Antoci, J P – sequence: 12 givenname: C L surname: Archer-Goode fullname: Archer-Goode, C L – sequence: 13 givenname: S M surname: Auerbach fullname: Auerbach, S M – sequence: 14 givenname: T D surname: Beam fullname: Beam, T D – sequence: 15 givenname: J M surname: Becker fullname: Becker, J M – sequence: 16 givenname: Y surname: Berger fullname: Berger, Y – sequence: 17 givenname: R J surname: Biester fullname: Biester, R J – sequence: 18 givenname: S D surname: Blick fullname: Blick, S D – sequence: 19 givenname: R S surname: Bradford fullname: Bradford, R S – sequence: 20 givenname: D T surname: Burzon fullname: Burzon, D T – sequence: 21 givenname: K surname: Cline fullname: Cline, K – sequence: 22 givenname: R E surname: D'Anna fullname: D'Anna, R E – sequence: 23 givenname: R R surname: Dmochowski fullname: Dmochowski, R R – sequence: 24 givenname: M surname: Efros fullname: Efros, M – sequence: 25 givenname: J M surname: Fialkov fullname: Fialkov, J M – sequence: 26 givenname: S surname: Freedman fullname: Freedman, S – sequence: 27 givenname: F surname: Gaylis fullname: Gaylis, F – sequence: 28 givenname: D surname: Ginsberg fullname: Ginsberg, D – sequence: 29 givenname: H surname: Goldman fullname: Goldman, H – sequence: 30 givenname: A surname: Gousse fullname: Gousse, A – sequence: 31 givenname: I surname: Grunberger fullname: Grunberger, I – sequence: 32 givenname: D S surname: Hale fullname: Hale, D S – sequence: 33 givenname: L surname: Hazan fullname: Hazan, L – sequence: 34 givenname: B L surname: Hertzman fullname: Hertzman, B L – sequence: 35 givenname: T C surname: Hlavinka fullname: Hlavinka, T C – sequence: 36 givenname: N A surname: Huff fullname: Huff, N A – sequence: 37 givenname: K surname: Jacoby fullname: Jacoby, K – sequence: 38 givenname: M W surname: Jalkut fullname: Jalkut, M W – sequence: 39 givenname: A R surname: Johnson fullname: Johnson, A R – sequence: 40 givenname: D surname: Josephson fullname: Josephson, D – sequence: 41 givenname: S surname: Kalota fullname: Kalota, S – sequence: 42 givenname: J surname: Kaminetsky fullname: Kaminetsky, J – sequence: 43 givenname: R surname: Kane fullname: Kane, R – sequence: 44 givenname: M M surname: Kaplan fullname: Kaplan, M M – sequence: 45 givenname: M surname: Khorsandi fullname: Khorsandi, M – sequence: 46 givenname: D surname: King-Menzner fullname: King-Menzner, D – sequence: 47 givenname: I W surname: Klimberg fullname: Klimberg, I W – sequence: 48 givenname: C G surname: Klutke fullname: Klutke, C G – sequence: 49 givenname: K surname: Krejci fullname: Krejci, K – sequence: 50 givenname: L S surname: Kriteman fullname: Kriteman, L S – sequence: 51 givenname: G E surname: Leach fullname: Leach, G E – sequence: 52 givenname: W W surname: Leng fullname: Leng, W W – sequence: 53 givenname: D U surname: Lipsitz fullname: Lipsitz, D U – sequence: 54 givenname: R R surname: Lotenfoe fullname: Lotenfoe, R R – sequence: 55 givenname: J surname: Lumerman fullname: Lumerman, J – sequence: 56 givenname: E J surname: Margolis fullname: Margolis, E J – sequence: 57 givenname: K surname: Maxwell fullname: Maxwell, K – sequence: 58 givenname: C K surname: Moore fullname: Moore, C K – sequence: 59 givenname: W surname: Moseley fullname: Moseley, W – sequence: 60 givenname: S surname: Mutchnik fullname: Mutchnik, S – sequence: 61 givenname: R J surname: Mynatt fullname: Mynatt, R J – sequence: 62 givenname: V surname: Nitti fullname: Nitti, V – sequence: 63 givenname: G surname: Park fullname: Park, G – sequence: 64 givenname: C K surname: Payne fullname: Payne, C K – sequence: 65 givenname: J M surname: Peters-Gee fullname: Peters-Gee, J M – sequence: 66 givenname: P surname: Pettit fullname: Pettit, P – sequence: 67 givenname: B J surname: Roberts fullname: Roberts, B J – sequence: 68 givenname: S surname: Rockove fullname: Rockove, S – sequence: 69 givenname: P K surname: Sand fullname: Sand, P K – sequence: 70 givenname: W surname: Schiff fullname: Schiff, W – sequence: 71 givenname: P surname: Shenot fullname: Shenot, P – sequence: 72 givenname: P surname: Siami fullname: Siami, P – sequence: 73 givenname: S surname: Siegel fullname: Siegel, S – sequence: 74 givenname: G surname: Simmons fullname: Simmons, G – sequence: 75 givenname: J surname: Snyder fullname: Snyder, J – sequence: 76 givenname: D surname: Sussman fullname: Sussman, D – sequence: 77 givenname: S E surname: Sutherland fullname: Sutherland, S E – sequence: 78 givenname: D N surname: Tietjen fullname: Tietjen, D N – sequence: 79 givenname: E surname: Torgerson fullname: Torgerson, E – sequence: 80 givenname: A surname: Viselli fullname: Viselli, A – sequence: 81 givenname: M A surname: Werner fullname: Werner, M A – sequence: 82 givenname: K surname: Whitmore fullname: Whitmore, K – sequence: 83 givenname: T surname: Williams fullname: Williams, T – sequence: 84 givenname: R surname: Wurzel fullname: Wurzel, R – sequence: 85 givenname: E surname: Zusman fullname: Zusman, E |
| Copyright | Copyright © 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: Copyright © 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. |
| CorporateAuthor | EMBARK Study Group |
| CorporateAuthor_xml | – name: EMBARK Study Group |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.juro.2016.10.109 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1527-3792 |
| ExternalDocumentID | 28012773 |
| Genre | Randomized Controlled Trial Clinical Trial, Phase III Journal Article |
| GroupedDBID | --- --K .55 .GJ .XZ 08P 0R~ 123 1B1 1CY 354 3O- 4.4 457 4G. 4Q1 4Q2 4Q3 53G 5RE 5VS 7-5 AAAAV AAEDT AAEDW AAGIX AAHPQ AAIQE AAJCS AAKAS AALRI AAMOA AAQFI AAQKA AAQQT AAQXK AASCR AASXQ AAXUO ABASU ABCQX ABDIG ABJNI ABLJU ABMAC ABOCM ABPPZ ABVCZ ABWVN ABXYN ABZZY ACGFS ACILI ACLDA ACOAL ACRPL ACXJB ACZKN ADGGA ADHPY ADMUD ADNKB ADNMO ADZCM AEBDS AEETU AENEX AFBFQ AFDTB AFEXH AFFNX AFNMH AFTRI AFUWQ AGHFR AGQPQ AHOMT AHQNM AHQVU AHRYX AHVBC AI. AINUH AITUG AIZYK AJCLO AJIOK AJNWD AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AMRAJ AOQMC ASGHL ASPBG AVWKF AZFZN BCGUY BELOY BYPQX C45 C5W CGR CS3 CUY CVF DIWNM DU5 EBS ECM EEVPB EIF EJD ERAAH EX3 F5P FCALG FDB FEDTE FGOYB GBLVA GNXGY GQDEL HLJTE HVGLF HZ~ H~9 IH2 IHE IKREB IKYAY IPNFZ J5H KMI L7B M41 MJL MO0 N4W NPM NQ- NTWIH O9- OAG OAH OB3 OBH ODMTH OGROG OHH OL1 OVD OWU OWV OWW OWY OWZ P2P QTD R2- RIG RLZ ROL RPZ SEL SES SJN SSZ TEORI TSPGW UDS UNMZH UV1 VH1 VVN WOW X7M XH2 XYM YFH YOC ZCG ZFV ZGI ZXP ZY1 ZZMQN 7X8 ABPXF ACVFH ADCNI ADGHP ADKSD ADSXY |
| ID | FETCH-LOGICAL-c326t-d3c5d39ba806038061bb18d1a4acef64e5f696ddb5847b4dcc82f56e4bb1559b2 |
| IEDL.DBID | 7X8 |
| ISSN | 1527-3792 |
| IngestDate | Sat Sep 27 16:53:31 EDT 2025 Tue Apr 08 05:56:59 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2S |
| Keywords | injections overactive urinary bladder intramuscular botulinum toxins onabotulinumtoxinA urinary incontinence |
| Language | English |
| License | Copyright © 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c326t-d3c5d39ba806038061bb18d1a4acef64e5f696ddb5847b4dcc82f56e4bb1559b2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| PMID | 28012773 |
| PQID | 1859755889 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1859755889 pubmed_primary_28012773 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-02-01 |
| PublicationDateYYYYMMDD | 2017-02-01 |
| PublicationDate_xml | – month: 02 year: 2017 text: 2017-02-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | The Journal of urology |
| PublicationTitleAlternate | J Urol |
| PublicationYear | 2017 |
| SSID | ssj0014572 |
| Score | 2.4527113 |
| Snippet | Overactive bladder affects 12% to 17% of the general population and almost a third experience urinary incontinence, which may severely impact health related... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | S216 |
| SubjectTerms | Acetylcholine Release Inhibitors - administration & dosage Acetylcholine Release Inhibitors - adverse effects Aged Botulinum Toxins, Type A - administration & dosage Botulinum Toxins, Type A - adverse effects Cholinergic Antagonists - therapeutic use Female Humans Injections, Intramuscular Male Middle Aged Neuromuscular Agents - administration & dosage Neuromuscular Agents - adverse effects Urinary Bladder - drug effects Urinary Bladder, Overactive - complications Urinary Bladder, Overactive - drug therapy Urinary Incontinence - drug therapy Urinary Incontinence - etiology Urinary Retention - chemically induced Urinary Tract Infections - chemically induced |
| Title | OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28012773 https://www.proquest.com/docview/1859755889 |
| Volume | 197 |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS-RAEG5clcWLuu76dinBo9lNOt15eBEVxYtjEIW5Df3EkTHRyYyI_8X_alWSwdPCgpeGQKoTuqurvq6q7o-xA5FIYok2QcRDHwhtdaAlPpLCSMt5Zo1qyCbSXi_r9_OiC7jVXVnlzCY2htpWhmLkf9Gv5KmUWZYfPz0HxBpF2dWOQuMbW4gRypBWp_3PLIKQDXkTMbfiQsp5d2imre96mI7p8F-U_GkvVfo3xGxczcXKV39ylS13IBNOWq34weZcuca-X3Vp9J_s_brEuZ9QEfr0cVK9DssTQPAKCAbhdlZ5DpWHor11tQYK18I1qr1q7COcjshijUGVFu7GzZleQFNTEe8E2YojuHH1dISS2IuC4h6dJcSHcIMC1ePwzdlDKCiCrys4a6vlR87ix3E5_GJ3F-e3Z5dBx9MQGAR_k8DGRto41yoLkzDGJtI6ymykBHbjE-GkT_LEWk0pWS2sMRn3MnECX8MNjebrbL6sSrfJwCTcIajzLlQWN6pcZ4bHnkdGhF4Jb7bY_mzgB7gOKLmhSldN68Hn0G-xjXb2Bk_thR0DTm44TePt_5DeYUucPHdTmL3LFjxaAbfHFs3LZFiPfzcKhm2vuPoAvCjdlQ |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=OnabotulinumtoxinA+for+the+Treatment+of+Patients+with+Overactive+Bladder+and+Urinary+Incontinence%3A+Results+of+a+Phase+3%2C+Randomized%2C+Placebo+Controlled+Trial&rft.jtitle=The+Journal+of+urology&rft.au=Nitti%2C+Victor+W&rft.au=Dmochowski%2C+Roger&rft.au=Herschorn%2C+Sender&rft.au=Sand%2C+Peter&rft.date=2017-02-01&rft.issn=1527-3792&rft.eissn=1527-3792&rft.volume=197&rft.issue=2S&rft.spage=S216&rft_id=info:doi/10.1016%2Fj.juro.2016.10.109&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1527-3792&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1527-3792&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1527-3792&client=summon |